Kyverna Therapeutics (KYTX) Live Share Price, Invest From India

Kyverna Therapeutics Stock Performance

as on January 15, 2026 at 2:29 am IST

Day's Low
Day's High
$8.60
Day's Price Range
$9.78
$9.16
6.11%
Downside
6.77%
Upside
52 Week's Low
52 Week's High
$1.78
52-Week Price Range
$13.67
$9.16
80.57%
Downside
49.24%
Upside

Kyverna Therapeutics share price movements today

Previous Close: $8.66
Open: $8.71
Volume: 1.6M
Day's Low - High: $8.60 - $9.78
52 Week Low - High: $1.78 - $13.67

Kyverna Therapeutics Historical Returns

1 Month Return: -15.34 %
3 Month Return: + 26.17 %
1 Year Return: + 178.42 %
3 Year Return: 0 %
5 Year Return: 0 %

Kyverna Therapeutics Stock Fundamentals & Key Indicators

Check Kyverna Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$516.2M

EPS (TTM)

-3.7055

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

PEG Ratio

EBITDA

-170.5M

Revenue (TTM)

Profit Margin

0.00%

Return On Equity TTM

-70.82%

Kyverna Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Kyverna Therapeutics with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Kyverna Therapeutics	BUY	$516.2M	NA	NA	0.00%
Alnylam Pharmaceuticals, Inc.	BUY	$48.9B	120.52%	1233.2	1.36%
Vertex Pharmaceuticals Incorporated	BUY	$116.6B	99.3%	31.95	31.35%
Beone Medicines Ltd	NA	$38.8B	NA	662.38	1.38%
Regeneron Pharmaceuticals, Inc.	BUY	$80.4B	45.61%	18.18	32.13%

Stock Returns calculator for Kyverna Therapeutics Stock including INR - Dollar returns

The Kyverna Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Kyverna Therapeutics investment value today

Current value as on today

₹2,82,746

Returns

₹1,82,746

(+182.75%)

Returns from Kyverna Therapeutics Stock

₹1,78,419 (+178.42%)

Dollar Returns*

₹4,327 (+4.33%)

Analyst Recommendation on Kyverna Therapeutics Stock

Based on 10 analysts

BUY

90.00%

Buy

10.00%

Hold

0.00%

Sell

Based on 10 analysts, 90% of analysts recommend a 'BUY' rating for Kyverna Therapeutics. Average target price of $29.6

Kyverna Therapeutics Share Price Target

Get share price movements and forecasts by analysts on Kyverna Therapeutics.

What analysts predicted

69.05%UPSIDE

Target Price

$29.6

Current Price

$9.16

Analyzed by

10 Analysts

Target

$29.60

Kyverna Therapeutics target price $29.6, a slight upside of 69.05% compared to current price of $9.16. According to 10 analysts rating.

Kyverna Therapeutics Stock’s Investor Sentiment and Interest

Search interest for Kyverna Therapeutics Stock has increased by 1389% in the last 30 days, reflecting an upward trend in search activity.

Time period: December 16, 2025 to January 15, 2026

Change:1389% versus previous 30 day period

Kyverna Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Total Revenue	-	-	-	-	-	-	2	-	-	-
Gross Profit	0	0	-17	0	0	-29	0	0	0	0
Operating Income	-13	-16	-21	0	-33	-38	-41	-47	-44	-38
EBITDA	-12	-14	-21	0	-28	-36	-36	-44	-41	-36
Interest Expense	0	0	0	0	0	0	0	0	0	0
Depreciation	0	0	0	0	0	0	0	0	0	0
Income Before Tax	-13	-15	-20	0	-28	-34	-37	-44	-42	-36
Income Tax Expense	-	-	0	0	-	-	-	-	-	-
Net Income	-13	-15	-20	0	-28	-34	-37	-44	-42	-36
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-1852.22%	0.00%	0.00%	0.00%

Kyverna Therapeutics Annual Profit & Loss

All numbers in Millions USD

	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Revenue	5	7	-	-
Gross Profit	5	7	-1	-2
Operating Income	-26	-29	-62	-142
EBITDA	-25	-27	-58	-125
Interest Expense	0	0	0	0
Depreciation	0	1	1	2
Income Before Tax	-26	-28	-60	-127
Income Tax Expense	0	0	0	-127
Net Income	-26	-28	-60	-127
Net Profit Margin	-465.88%	-411.29%	0.00%	0.00%

Kyverna Therapeutics Quarterly Cash Flow

All numbers in Millions USD

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Net Income	-15	-20	-26	-28	-34	-37	-44	-42	-36
Operating Cash Flow	-11	-18	-25	-24	-27	-37	-44	-31	-43
Investing Cash Flow	-54	31	-122	-67	0	29	5	29	22
Financing Cash Flow	34	-1	338	0	0	0	0	0	1
Change in Cash	-30	11	189	-92	-26	-8	-39	-3	-19

Kyverna Therapeutics Annual Cash Flow

All numbers in Millions USD

	Dec 2022	Dec 2023	Dec 2024
Net Income	-28	-60	-127
Operating Cash Flow	-36	-52	-114
Investing Cash Flow	-14	-8	-160
Financing Cash Flow	11	58	337
Change in Cash	-38	-3	61

Insights on Kyverna Therapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Best in 1 Year
In the last 1 year, KYTX has outperformed top 5 stocks with highest market-cap in its industry
NEGATIVE IMPACT
Price Dip
In the last 1 month, KYTX stock has moved down by -15.3%

About Kyverna Therapeutics

Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases. The Company’s lead chimeric antigen receptor (CAR) T-cell therapy candidate, KYV-101, is advancing through clinical development with Phase II trials for stiff person syndrome and myasthenia gravis, and two ongoing multi-center Phase I/II trials for patients with lupus nephritis. KYV-101 is an autologous, fully human CD19 CAR T-cell product candidate incorporating highly potent CD28 co-stimulation. The Company is also harnessing investigator-initiated trials and other KYSA studies, including in multiple sclerosis and systemic sclerosis, to inform the next priority indications for the Company to advance into late-stage development. Its pipeline includes next generation CAR T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.

Organisation	Kyverna Therapeutics
Headquarters	5980 Horton Street, Emeryville, CA, United States, 94608
CEO	Mr. Warner Biddle
E-voting on shares	Click here to vote

Key Management of Kyverna Therapeutics

Name	Title
Mr. Warner Biddle	CEO & Director
Dr. Marc Grasso M.D.	Chief Financial Officer
Ms. Cara Bauer Ph.D.	Chief Human Resources Officer
Mr. Dan Maziasz	Chief Business Officer
Dr. Naji H. Gehchan M.B.A., M.D.	Chief Medical & Development Officer
Dr. Sham Dholakia DPHIL, M.D.	Chief Product Officer
Ms. Karen Walker	Chief Technology Officer
Dr. Tom Van Blarcom Ph.D.	Senior VP & Head of Research
Ms. Jessica Serra	Head of Investor Relations
Ms. Tracy Rossin	Senior Vice President of Corporate Affairs & Communications and Investor Relations

FAQs

What is Kyverna Therapeutics share price today?

Kyverna Therapeutics share price today is $9.16 as on January 15, 2026 at 2:29 am IST at the close of the market. Kyverna Therapeutics share today touched a day high of $9.78 and a low of $8.6.

What is the 52 week high and 52 week low for Kyverna Therapeutics share?

Kyverna Therapeutics share touched a 52 week high of $13.67 on December 15, 2025 and a 52 week low of $1.78 on April 17, 2025. Kyverna Therapeutics stock price today i.e. January 15, 2026 at 2:29 am IST is closed at $9.16,which is 32.99% down from its 52 week high and 414.61% up from its 52 week low.

What is Kyverna Therapeutics's market capitalisation today?

Kyverna Therapeutics market capitalisation is $0.00T as on January 15, 2026 at 2:29 am IST.

How to invest in Kyverna Therapeutics Stock (KYTX) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Kyverna Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Kyverna Therapeutics Shares that will get you 0.1638 shares as per Kyverna Therapeutics share price of $9.16 per share as on January 15, 2026 at 2:29 am IST.

What is the minimum amount required to buy Kyverna Therapeutics Stock (KYTX) from India?

Indian investors can start investing in Kyverna Therapeutics (KYTX) shares with as little as ₹90.274 or $1 (as of January 15, 2026 at 2:36 pm IST) using the INDmoney app.
For example: If you want to invest $10 or ₹902.74 in Kyverna Therapeutics stock (as per the Rupee-Dollar exchange rate as on January 15, 2026 at 2:36 pm IST). Based on Kyverna Therapeutics share’s latest price of $9.16 as on January 15, 2026 at 2:29 am IST, you will get 1.0917 shares of Kyverna Therapeutics. Learn more about fractional shares .